Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn’s Disease
Lauren V. Collen
Abstract
Lay Summary A pediatric patient with Crohn’s disease refractory to anti-tumor necrosis factor therapy, vedolizumab, ustekinumab, and 6-mercaptopurine achieved rapid clinical remission with upadacitinib. This is the first report of successful use of upadacitinib in pediatric inflammatory bowel disease.
Topics & Concepts
VedolizumabMedicineUstekinumabRefractory (planetary science)Inflammatory bowel diseaseCrohn's diseaseInternal medicineCrohn diseaseMercaptopurineGastroenterologyAdalimumabDiseaseAstrobiologyPhysicsInflammatory Bowel DiseaseMicroscopic ColitisAcute Lymphoblastic Leukemia research